Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

Published:2009-11-24 Issue:1 Volume:102 Page:68-72
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bengala C,Bertolini F,Malavasi N,Boni C,Aitini E,Dealis C,Zironi S,Depenni R,Fontana A,Del Giovane C,Luppi G,Conte P

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6605458.pdf

Reference28 articles.

1. Adjei AA, Christian M, Ivy P (2009) Novel designs and end points for phase II clinical trials. Clin Cancer Res 15: 1866–1872

2. Beeram M, Patnaik A, Rowinsky EK (2005) RAF a strategic target for therapeutic development against cancer. J Clin Oncol 23: 6771–6790

3. Berardi R, Scartozzi M, Freddari F, Squadroni M, Santinelli A, Bearzi I, Fabris G, Cascinu S (2006) Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review. Cancer Treat Rew 32: 333–347

4. Clark JW, Meyerhardt JA, Sahani DV, Namasivayam S, Abrams TA, Stuart K, Bhargava P, Blaszkowsky LS, Jain SR, Zhu AX (2007) Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic biliary tract and gallbladder cancers. J Clin Oncol 25: 18S (Suppl; abstract 4625)

5. Dal Lago L, D’Hondt V, Awada A (2008) Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumor. Oncologist 13: 845–858

Cited by 194 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma;Cancers;2024-04-26

2. Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis;Future Oncology;2024-04

3. Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma;Frontiers in Oncology;2023-12-07

4. Angiogenesis: the Yin and Yang in intrahepatic cholangiocarcinoma;Hepatoma Research;2023-08-23

5. Moving beyond single-agent checkpoint inhibition in biliary tract cancers: what is the next frontier?;Immunotherapy;2023-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3